Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company listed on the NASDAQ stock exchange under the symbol "MIRM," operates in the rare and orphan disease sector. The company is dedicated to the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Mirum Pharmaceuticals has a significant presence in the United States and international markets.

Mirum Pharmaceuticals generates revenue through the development and commercialization of its novel therapies for rare and orphan diseases. The company's primary products include LIVMARLI, Cholbam, and Chenodal. LIVMARLI is a novel, orally administered, minimally-absorbed ileal bile acid transporter inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis. Cholbam is approved for the treatment of bile acid synthesis disorders and adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome. Chenodal is approved for the treatment of radiolucent stones in the gallbladder and has received medical necessity recognition by the FDA for the treatment of cerebrotendinous xanthomatosis.

Mirum Pharmaceuticals has a strong position within the industry, competing against other biopharmaceutical companies that focus on developing and commercializing novel therapies for rare and orphan diseases. The company's competitive advantages include its strong product pipeline, its ability to commercialize and advance regulatory approvals of its products, and its ability to develop and commercialize novel therapies for debilitating rare and orphan diseases. Mirum Pharmaceuticals' customers include patients with rare and orphan diseases, healthcare providers, and payers.

The company's revenue generation is supported by its strong product pipeline, with several clinical trials underway or planned. Mirum Pharmaceuticals is conducting adaptive, potentially registrational, Phase 2b clinical trials of volixibat in primary sclerosing cholangitis and primary biliary cholangitis. The company expects to submit a new drug application for Chenodal for the treatment of cerebrotendinous xanthomatosis to the FDA in the first half of 2024.

Mirum Pharmaceuticals has a number of license and finance agreements in place, including an assignment and license agreement with Shire International GmbH, which granted the company an exclusive, royalty-bearing, sublicensable, worldwide license to develop, have developed, make, have made, use, sell, have sold, offer for sale or import the Shire Licensed Products, including LIVMARLI and volixibat, for the therapeutic or prophylactic application in human health. Under the agreement, Mirum Pharmaceuticals is required to pay Shire up to an aggregate of $109.5 million upon the achievement of certain clinical development and regulatory milestones for LIVMARLI in the PFIC and ALGS indications, and a $25.0 million payment upon regulatory approval of LIVMARLI for each and every other indication.

The company has a license agreement with Pfizer Inc., which granted the company an exclusive, worldwide license to Pfizer's know-how related to LIVMARLI, and a license agreement with Satiogen, which granted the company an exclusive, worldwide license to develop, have developed, make, have made, use, sell, have sold, offer for sale or import certain products for the diagnosis, treatment, prevention, mitigation and cure of human diseases and disorders. These agreements support the company's growth and development.